Lilly GBDE
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Once-Daily Liraglutide in Patients with Type 2 Diabetes (AWARD-6: Assessment of Weekly AdminstRation of LY2189265 in Diabetes – 6)
| Protocol | H9X-MC-GBDE |
|---|
| Identifier | H9X-MC-GBDE Site Number 103 |
|---|
| UID | 24e0eb21-1044-4b8a-9eb6-6f4dbd568766 |
|---|
| Status | Done - Archived |
|---|
| Phase | 3b |
|---|
| Category | Diabetes Type 2 / Adult |
|---|
| Launch Year | 2012 |
|---|
| NCT Number | - |
|---|
| Created | 2012-05-15 16:18 |
|---|
| Last Updated | 2012-05-15 16:18 |
|---|
Description
Key Elements:
• Study purpose: To demonstrate that once-weekly dulaglutide 1.5 mg is noninferior to once-daily liraglutide 1.8 mg in patients who are on monotherapy metformin (>1,500 mg daily)
• Study drug: Dulaglutide is novel, long-acting GLP-1 analogue, administered once-weekly subcutaneously. GLP-1s have been shown to help reduce weight, have a positive impact on cardiovascular outcomes, and even help lower blood pressure. The most common side effect of GLP-1 has been mild-to-moderate gastrointestinal issues; nausea, vomiting, diarrhea.
• 11 visits (33 weeks/8 months)
• Stipend: $42 per visit
• HbA1c >7.0% to <10.0%
Comment
No comment.
